PAOLO ANDERLINI to Disease Progression
This is a "connection" page, showing publications PAOLO ANDERLINI has written about Disease Progression.
Connection Strength
0.046
-
Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Ann Oncol. 2016 07; 27(7):1317-23.
Score: 0.015
-
Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant. Leuk Lymphoma. 2012 Aug; 53(8):1525-9.
Score: 0.011
-
Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant. 2007 Apr; 13(4):454-62.
Score: 0.008
-
Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. Bone Marrow Transplant. 2004 May; 33(10):1015-23.
Score: 0.007
-
Respiratory syncytial virus infections in autologous blood and marrow transplant recipients with breast cancer: combination therapy with aerosolized ribavirin and parenteral immunoglobulins. Bone Marrow Transplant. 2001 Aug; 28(3):271-5.
Score: 0.005